RT Journal Article
T1 T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin.
A1 Raspollini, Maria Rosaria
A1 Luque, Rafael J
A1 Menendez, Carmen Luz
A1 Bollito, Enrico
A1 Brunelli, Matteo
A1 Martignoni, Guido
A1 Montironi, Rodolfo
A1 Cheng, Liang
A1 Blanca, Ana
A1 Baroni, Gianna
A1 Minervini, Andrea
A1 Lopez-Beltran, Antonio
K1 Bladder cancer
K1 E-cadherin
K1 Progression
K1 Survivin
K1 T1
K1 Topoisomerase-IIα
K1 p16
AB High-grade papillary urothelial carcinoma with subepithelial connective tissue invasion (T1HG) is an aggressive disease at high risk of progression after transurethral resection/Bacillus Calmette-Guerin standardized therapy. The European Organization for Research and Treatment of Cancer has identified T1HG bladder carcinoma that is single and ≤3 cm in the largest dimension at first diagnosis as a category in which the prognosis cannot be further stratified based on conventional criteria. This category may benefit from biomarker analysis as a valuable tool to determine the patient's outcome. To further the issue of biomarkers in predicting aggressiveness in single T1HG bladder carcinoma ≤3 cm in greatest dimension at first diagnosis, we have conducted a validation study of the biomarker risk score set previously reported by our group. The study set included immunohistochemical detection of galectin-3, CD44, E-cadherin (E-CAD), CD138, p16, survivin, HYAL-1, and topoisomerase-IIα in 92 randomly selected specimens at participating institutions. Topoisomerase-IIα expression was identified as a predictor of disease-free survival. p16, survivin, and E-CAD expression predicted progression-free survival, but p16 and E-CAD also predicted overall survival. The current study validates a panel of immunohistochemical markers with the potential of being implemented in practice and supports the use of biomarkers in predicting aggressiveness in patients with first diagnosis of single T1HG bladder carcinoma ≤3 cm in greatest dimension and therefore in identifying patients who need closer surveillance or earlier aggressive treatment.
PB Elsevier
YR 2016
FD 2016-06-28
LK http://hdl.handle.net/10668/10314
UL http://hdl.handle.net/10668/10314
LA en
NO Raspollini MR, Luque RJ, Menendez CL, Bollito E, Brunelli M, Martignoni G, et al. T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin. Hum Pathol. 2016 Nov;57:78-84
DS RISalud
RD Apr 11, 2025